The estimated Net Worth of William D. Jr. Mc Clellan is at least $3.75 Milion dollars as of 28 July 2023. Mr. Clellan owns over 5,000 units of Reata Pharmaceuticals Inc stock worth over $1,037,090 and over the last 8 years he sold RETA stock worth over $2,114,170. In addition, he makes $599,306 as Independent Director at Reata Pharmaceuticals Inc.
Sign up
Mr. McClellan RETA stock SEC Form 4 insiders trading
William has made over 4 trades of the Reata Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of RETA stock worth $822,450 on 28 July 2023.
The largest trade he's ever made was selling 5,000 units of Reata Pharmaceuticals Inc stock on 28 July 2023 worth over $822,450. On average, William trades about 682 units every 103 days since 2016. As of 28 July 2023 he still owns at least 6,017 units of Reata Pharmaceuticals Inc stock.
You can see the complete history of Mr. Clellan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William McClellan biography
William D. McClellan Jr., CPA serves as Independent Director of the Company. He is an independent Director of Reata Pharmaceuticals Inc. Mr. McClellan, Jr. has served as the Chief Financial Officer of Aerin Medical Inc. since January 2018. Mr. McClellan, Jr. is a financial management consultant to healthcare and life sciences companies, serving as the managing member of Goodwater Consulting, LLC since March 2017. From June 2004 until June 2016, Mr. McClellan, Jr. was the Chief Financial Officer and Executive Vice President, Finance at On-X Life Technologies Holdings, Inc. Prior to June 2004, Mr. McClellan, Jr. held financial and accounting positions at various healthcare and other companies and was a certified public accountant serving as an auditor with PricewaterhouseCoopers for nine years. He currently serves on the board of directors of Apollo Endosurgery, Inc., a publicly-traded company, and chairs its audit committee. Mr. McClellan, Jr. received a B.B.A. in accounting from Abilene Christian University and is a certified public accountant. Our Board believes that Mr. McClellan, Jr. is qualified to serve on our Board due to his extensive experience in finance and accounting roles in the healthcare and life sciences industry and in serving as a certified public accountant at a large public accounting firm.
What is the salary of William McClellan?
As the Independent Director of Reata Pharmaceuticals Inc, the total compensation of William McClellan at Reata Pharmaceuticals Inc is $599,306. There are 11 executives at Reata Pharmaceuticals Inc getting paid more, with Manmeet Soni having the highest compensation of $12,612,200.
How old is William McClellan?
William McClellan is 60, he's been the Independent Director of Reata Pharmaceuticals Inc since 2017. There are 5 older and 10 younger executives at Reata Pharmaceuticals Inc. The oldest executive at Reata Pharmaceuticals Inc is Michael D. Wortley, 73, who is the Exec. VP & Chief Legal Officer.
What's William McClellan's mailing address?
William's mailing address filed with the SEC is 2801 Gateway Dr #150, Irving, TX 75063, USA.
Insiders trading at Reata Pharmaceuticals Inc
Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy oraz Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.
What does Reata Pharmaceuticals Inc do?
reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
What does Reata Pharmaceuticals Inc's logo look like?
Complete history of Mr. Clellan stock trades at Apollo Endosurgery Inc i Reata Pharmaceuticals Inc
Reata Pharmaceuticals Inc executives and stock owners
Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Manmeet Soni,
Chief Financial Officer, Chief Operating Officer, Executive Vice President -
J. Warren Huff,
Chairman of the Board, President, Chief Executive Officer -
Colin Meyer,
Executive Vice President, Chief Research and Development Officer -
Michael Wortley,
Executive Vice President, Chief Legal Officer -
Dawn Bir,
Executive Vice President, Chief Commercial Officer -
Manmeet Singh Soni,
COO, CFO & Pres -
J. Warren Huff,
Chairman & CEO -
Dr. Colin J. Meyer M.D.,
Exec. VP & Chief Innovation Officer -
Michael D. Wortley,
Exec. VP & Chief Legal Officer -
Dawn Carter Bir,
Exec. VP & Chief Commercial Officer -
Jack Nielsen,
Independent Director -
William McClellan,
Independent Director -
William Rose,
Independent Director -
R. Kent McGaughy,
Independent Director -
Vineet Jindal,
Vice President, Corporate Communications and Strategy -
Martin Edwards,
Independent Director -
Seemi Khan,
Chief Medical Officer -
Andrea Loewen,
Vice President - Global Regulatory Affairs -
Kevin Johnston,
Chief Technical Officer, Vice President -
Steve Harman,
VP & Chief HR Officer -
Dakota Gallivan,
VP & Chief Healthcare Compliance Officer -
Dr. W. Christian Wigley Ph.D.,
Sr. VP & Chief Scientific Officer -
Bhaskar Anand,
VP & Chief Accounting Officer -
William Puffin Partners, L....,
-
Dennis K. Stone,
Director -
Elaine Castellanos,
VP, Chief Accounting Officer -
Holdings A/S Novo,
10% owner -
James Edward Bass,
Director -
James W Jr Traweek,
-
Inc Cpmg,
-
Inc. Abb Vie,
10% owner -
Keith Wayne Ward,
See Remarks -
William Rose Evelyn P.Edwar...,
-
William Puffin Partners, L....,
-
Antal Rohit Cpmg Inc Desai,
-
William Montrose Investment...,
-
William Charles Henry Rose ...,
-
William Puffin Partners, L....,
-
William Estate Of Edward W....,
-
Jason Douglas Wilson,
Executive VP of Operations -
Pharma Llcstapleton Craig R...,
-
Christy J. Oliger,
Director -
Shamim Ruff,
Director -
Bhaskar Anand,
SVP, Chief Accounting Officer -
Steven Ryder,
Director -
Samina Khan,
SVP, Chief Medical Officer -
Rajiv Patni,
EVP, Chief R&D Officer